Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Sarah A Meadows, Huong (Marie) Nguyen, M.D., Christophe Queva, PhD, Brian J. Lannutti, PhD, Adam Kashishian, Susie Jun, MD, PhD, Steven E. Coutre, MD, Roger Dansey, MD, Jason Gotlib, MD, MS

Blood (2013) 122 (21): 4065.

https://doi.org/10.1182/blood.V122.21.4065.4065

Published: 2013

Journal Articles

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

Russell T Burke, Astrid Clarke, Sarah A Meadows, Marc M Loriaux, MD, PhD, Jennifer B Dunlap, MD, Guang Fan, MD, PhD, Patricia Maciejewski, Julie Di Paolo, Brian J. Lannutti, PhD, Brian J. Druker, Stephen E Spurgeon, MD

Blood (2012) 120 (21): 3876.

https://doi.org/10.1182/blood.V120.21.3876.3876

Published: 2012

Journal Articles

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

Sarah A. Meadows, Francisco Vega, Adam Kashishian, Dave Johnson, Volker Diehl, Langdon L. Miller, Anas Younes, Brian J. Lannutti

Blood (2012) 119 (8): 1897–1900.

https://doi.org/10.1182/blood-2011-10-386763

Published: 2012

Includes: Supplemental data

Journal Articles

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

Sarah A Meadows, Adam Kashishian, David Johnson, Roger G Ulrich, Langdon L Miller, Brian J. Lannutti, PhD

Blood (2011) 118 (21): 3730.

https://doi.org/10.1182/blood.V118.21.3730.3730

Published: 2011

Journal Articles

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

Julia Hoellenriegel, Sarah A. Meadows, Mariela Sivina, William G. Wierda, Hagop Kantarjian, Michael J. Keating, Neill Giese, Susan O'Brien, Albert Yu, Langdon L. Miller, Brian J. Lannutti, Jan A. Burger

Blood (2011) 118 (13): 3603–3612.

https://doi.org/10.1182/blood-2011-05-352492

Published: 2011

Includes: Supplemental data

Journal Articles

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Brian J. Lannutti, Sarah A. Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey W. Tyner, Marc M. Loriaux, Mike Deininger, Brian J. Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese

Blood (2011) 117 (2): 591–594.

https://doi.org/10.1182/blood-2010-03-275305

Published: 2011

Includes: Supplemental data

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

Sarah A Meadows, BS, Adam Kashishian, BS, Dave Johnson, Volker Diehl, Brian Lannutti, PhD

Blood (2010) 116 (21): 3926.

https://doi.org/10.1182/blood.V116.21.3926.3926

Published: 2010

Journal Articles

Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia

Julia Hoellenriegel, Sarah A Meadows, William G. Wierda, MD, PhD, Michael J Keating, MD, Brian Lannutti, PhD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 48.

https://doi.org/10.1182/blood.V116.21.48.48

Published: 2010

Journal Articles

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.

Brian J Lannutti, Sarah A Meadows, Adam Kashishian, Bart Steiner, Galina Pogosov, Olga Sala-Torra, Amy J Johnson, John C. Byrd, Jerald Radich, Neill A. Giese

Blood (2009) 114 (22): 286.

https://doi.org/10.1182/blood.V114.22.286.286

Published: 2009

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Brian J Lannutti, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Sarah May, Amy J. Johnson, Roger G. Ulrich, Albert Yu, Michael W. Gallatin, John C. Byrd, MD, Kamal D. Puri, Neill A. Giese

Blood (2008) 112 (11): 16.

https://doi.org/10.1182/blood.V112.11.16.16

Published: 2008

NARROW

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only